Hans Ivar Robinson
Algemeen Directeur bij Birk Venture AS
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Anders Tuv | M | 46 |
Nextera AS
 Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway.
Zelluna Immunotherapy AS
 Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | 12 jaar |
| Bent K. Jakobsen | M | - |
Accession Therapeutics Limited
 Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors.
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | - |
| Per-Oluf Olsen | M | 68 |
Pronova BioPharma ASA
 Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway.
Birk Venture AS
 Birk Venture AS Investment ManagersFinance Birk Venture AS (Birk Venture) is an independent Scandinavian venture capital firm which was founded in 2010 by Hans Ivar Robinson. Based in Oslo, Norway, the firm focuses exclusively on the life science industry, utilizing their industry experience and international network to partner with young companies with significant growth prospects.
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | 16 jaar |
| Geir Åge Løset | M | - |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | 15 jaar |
| Namir Hassan | M | - |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | - |
| Anders Holm | M | - |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | 7 jaar |
| Martin Welschof | M | 63 |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | 11 jaar |
| Nicholas Cross | M | - |
Accession Therapeutics Limited
Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | - |
| Hans Peter Bøhn | M | 69 |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | 7 jaar |
| Gustav Gaudernack | M | - |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | - |
| Johnny Zou | M | - |
Accession Therapeutics Limited
Accession Therapeutics Limited BiotechnologyHealth Technology Accession Therapeutics Limited is a British biotech company that is developing novel immuno-oncology therapeutics to eradicate cancers by harnessing the immune system more powerfully than ever before. The company is based in Oxford, UK and was founded in 2020 by Bent K. Jakobsen, who has been the CEO since then. The company's product, Trocept, is the first approach that meets the three requirements of being highly specific, broad in action to kill all cancer cell variants present, and potent in activating the full immune system arsenal local to the tumour. The team is built around successful biotech entrepreneurs experienced in taking projects through to the clinic and is supported by a Board comprising experienced international healthcare investors. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Thomas Settevik | M | 64 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | 4 jaar |
| Hilde Hermansen Steineger | M | 58 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | 8 jaar |
| Göran Gannedahl | M | 71 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Rikke Kathrine Tobi Reinemo | F | 49 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Jo Olav Lunder | M | 62 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | 5 jaar |
| Siri Fürst | F | 66 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Jo Erik Johnsrud Klaveness | M | 71 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Miguel Forte | M | 63 |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway. | 2 jaar |
| Charlotte Berg-Svendsen | F | 49 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Camilla Hudtloff | F | 53 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Knut Sandvold | M | 63 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Thomas Andersen | M | 51 |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Nextera AS provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer. It offers platform for protein engineering and evolution, such as life sciences, drug discovery, and lead optimization fields. The firm’s core competence lies within protein engineering and evolution utilizing its technology to epitope discovery and epitope validation, as well as lead-candidate generation and validation in-vitro. The company was founded by Geir Åge Løset and Inger Sandlie in 2009 and is headquartered in Oslo, Norway. | - |
| Carsten Hjorth Jensen | M | 61 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Alexis Garras | M | 58 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | - |
| Jens Bjørheim | M | - |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Pronova BioPharma ASA engages in the research, development, and manufacture of lipid therapies derived from nature. Its products are used for providing enteral and parenteral nutrition solutions, and dietary supplements; and treating metabolic and cardiovascular disorders. The company was founded in 1838 and is headquartered in Lysaker, Norway. | 2 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Noorwegen | 24 | 92.31% |
| Verenigd Koninkrijk | 3 | 11.54% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Hans Ivar Robinson
- Persoonlijk netwerk
